I started this one the way I start most of these: somebody sent me a screenshot. A peptide called SS-31, supposedly the thing that “recharges your mitochondria,” being sold on a website that also sells research chemicals labeled, in the same breath, not for human consumption. That contradiction is usually where the story is. So I went looking.
Here is the claim, more or less verbatim from three different sellers: SS-31 gets inside your cells, finds the folded inner membrane where energy actually gets made, and fixes whatever’s gone wrong there. Said with enough confidence, it sounds like a fact. Turns out, part of it is.
What the record actually shows
The biology checks out, and I want to say that plainly before I start picking the thing apart, because a columnist who only tears things down isn’t being any more honest than a salesman who only builds them up. SS-31, chemical name elamipretide, is a four-amino-acid peptide that really does behave differently from the usual peptide-and-receptor story. It gets into the cell and parks itself on the inner mitochondrial membrane, where it binds a lipid called cardiolipin. A 2013 paper in the Journal of the American Society of Nephrology measured this directly and reported that “SS-31 binds with high affinity to cardiolipin,” helping the membrane hold its shape and restoring energy output in mitochondria that had been starved of oxygen [P1]. A 2025 review lands on the same mechanism [P2]. That part of the pitch is not marketing invention. It’s real chemistry.
But real chemistry in a dish is not the same thing as a benefit in a person, and elamipretide has actually gone through the human-trial gauntlet, which is more than most gray-market peptides can say. So I pulled the trial record, in order, because the order turns out to matter more than any single result.
2018: a phase 1/2 dose-escalation study in Neurology tested short-term IV elamipretide in patients with primary mitochondrial myopathy. At the highest dose, people walked meaningfully farther after five days. The authors’ own words: it “increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns” [P4]. A genuine, promising early signal. Nobody’s lying about this part.
2023: the bigger, harder test. MMPOWER-3, the pivotal phase 3 trial, published in Neurology. 218 adults with genetically confirmed primary mitochondrial myopathy, randomized to 40 mg a day of subcutaneous elamipretide or placebo, for 24 weeks, measured on the six-minute walk test and total fatigue [P3]. Result: no statistically significant difference from placebo on either co-primary endpoint. The trial missed its primary and secondary endpoints [P3]. Flat out.
2025: the FDA grants elamipretide accelerated approval, under the brand name Forzinity. Not for fatigue, not for energy, not for the myopathy trial that just failed. For Barth syndrome, an ultra-rare inherited disorder, and only in patients weighing at least 30 kg [P5][P6].
Lay those three dates next to each other and you get the whole story of how this peptide gets sold to you. The pitch you read online is almost always built from 2018. The thing that actually happened next, in 2023, quietly disappears. And the approval you see waved around like a stamp of legitimacy is from 2025, and covers a disease you almost certainly do not have. Three true facts, arranged to tell you something none of them says on its own. That’s the trick, and once you see the timeline it’s hard to unsee.
The uncomfortable part
So what’s it actually like to take, in the trials where somebody was watching? Reasonably boring, which in medicine is a compliment. Injection-site reactions were the main complaint, and it was generally tolerated [P3]. Fine. But notice what that sentence is actually claiming. It’s describing a specific manufactured product, at a known dose, given to screened patients, under supervision. It says nothing about a vial from a research-chemical site sitting in your refrigerator, nothing about dosing yourself off a forum post, and it is not a reason to inject something that, in the one large trial built to prove it works for the reason you want it, didn’t.
Here’s the part I keep coming back to. For years, the only practical way to get SS-31 was through a research-chemical retailer: add to cart, tick a box swearing it’s “for laboratory research only, not for human consumption,” and a padded envelope shows up. That sentence on the label isn’t boilerplate. It’s the entire legal foundation the business sits on. The instant something is sold for a person to inject, it becomes an unapproved drug, so the label exists specifically to say it isn’t that.
In 2026, the regulatory screws tightened on that whole trade, and the contrast between the two ways to obtain this peptide got a lot starker. On one side: a clinician reviews you, writes a prescription when it’s appropriate, a licensed compounding pharmacy prepares the actual product, and somebody checks in afterward. On the other: a website that legally cannot do any of that and says so, in writing, on the label. Given how thin and mixed the human evidence actually is, being the only person accountable for what’s in that vial strikes me as a worse bet now than it was a year ago.
Who actually checked out, and who’s just shipping powder
I looked at three research-chemical sellers people kept naming: Core Peptides, Swiss Chems, Biotech Peptides. All three are the same animal wearing different labels. US-based, research-use-only catalogs, SS-31 sold alongside a broad menu of other peptides. Core Peptides may publish a certificate of analysis, but that’s a document the seller chose to produce, not an independent guarantee of what’s in the vial. None of the three involves a clinician, a prescription, a pharmacy, or any follow-up. I can’t rank them against each other on quality, and neither can you, because without independent batch testing there’s no way to know whose SS-31 is actually clean. That’s not an oversight. That uncertainty is baked into the business model.
Here’s my honest read: buying from any of these three means nobody decided whether this was appropriate for you, nobody stands behind the contents of the vial, the FDA has not reviewed it for identity or purity, and if it’s underdosed or contaminated, there’s no recall and no one accountable. Stack that on top of a compound whose biggest trial for your actual use case failed, and you’re carrying the full weight of an unregulated injectable for a benefit nobody has demonstrated. You are, in effect, running your own uncontrolled trial, on yourself, with no one collecting the data.
Which is why, when I looked at the supervised end of the market, FormBlends is the one I’d point you to first, and for reasons that go beyond convenience. It’s a licensed telehealth provider, not a chemical warehouse. SS-31 through FormBlends comes with an actual clinician evaluation, a prescription written when appropriate, and preparation through a licensed 503A compounding pharmacy, at physician-supervised pricing that runs roughly $200 to $500 a month. Same peptide the gray market mails you in a vial marked “not for human consumption.” Completely different chain of custody.
What actually earned it the top spot, in my digging, wasn’t just the paperwork. It was the candor. A responsible provider doesn’t let a narrow rare-disease approval do the marketing work of a broad one. It tells you, plainly, that elamipretide’s FDA approval covers Barth syndrome and nothing else, that the primary mitochondrial myopathy trial missed its endpoints, and that energy, recovery, and longevity uses remain investigational. That’s the opposite of how the exact same molecule gets sold two clicks away on a research-chemical site. And the pharmacy piece isn’t decorative: a 503A pharmacy compounds against your individual prescription under USP standards, with a licensed pharmacist accountable for what ends up in your vial, which is a different universe from a seller’s self-issued spec sheet.
I’ll give the trade-off its due too, because a review that only flatters one side isn’t a review. Going through a clinician means an intake process and a prescription, not instant checkout, so it’s slower. And supervision doesn’t rewrite the science. A clinician can’t make a failed trial pass, or turn an investigational use into a proven one. What supervision buys you is everything the research-chemical model is structurally incapable of offering: someone screening you, a regulated pharmacy standing behind the product, an honest accounting of what the data actually shows, and somebody to call afterward. If you want to log your dose and any symptoms between check-ins, FormBlends’ tracker app does that logging job, nothing more, it’s not a prescription and not a checkout.
HealthRX.com (healthrx.com) sits in the same supervised tier, in second place, built on the identical logic: clinician oversight first, a required prescription, a licensed pharmacy dispensing, and the same honest caveat that the FDA approval is Barth-only while the popular uses remain investigational. If you’re picking between the two supervised options, I’d make it a practical decision, whichever one is licensed in your state and whose intake process fits you. Both operate inside a real telehealth framework, which is the credential that actually matters here.
MeriHealth takes third in this supervised tier, for the same structural reasons: clinician evaluation, required prescription, licensed compounding pharmacy dispensing, and the same acknowledgment that compounded medications aren’t FDA-approved and that uses outside Barth syndrome are investigational. What sets it apart is a women’s-health orientation, with intake and clinical review built around hormonal, metabolic, and reproductive context that general platforms tend to treat as an afterthought. If that fits your situation, it’s worth a look alongside the two above it.
WomenRX rounds out the tier in fourth place, and qualifies for the same reasons: physician supervision, a required prescription, dispensing through a licensed compounding pharmacy, and the standing caveat that compounded GLP-1 and peptide therapies aren’t FDA-approved. Its distinguishing pitch is a clinical model built entirely around women’s health, meaning intake, dosing context, and follow-up default to female physiology instead of treating it as a variant. Confirm licensure in your own state and compare intake against the other supervised options before deciding.
My verdict
For the reason most people actually want this peptide, energy, fatigue, recovery, longevity, there is no solid human evidence it does anything, and there’s a large, well-run trial sitting right next to that hope that came back negative. The mechanism is genuinely interesting and it did earn a narrow approval, in one rare disease most readers of this article don’t have. Mechanism is a reason to run a trial, not proof the trial will go your way, and in this case the trial that mattered most for the everyday pitch already ran, and it lost.
If you decide to try it anyway, the choice in front of you isn’t complicated. Go through someone who screens you, sources it through an actual pharmacy, and will tell you the timeline I just laid out without flinching, or go to a site that ships you a vial stamped “not for human consumption” and asks you nothing at all. That’s the whole difference between SS-31 the medication and SS-31 the gamble, and after going through the record, I know which side of that line I’d want to be standing on.
What is SS-31 peptide and how does it work in the body?
SS-31, also known as elamipretide, is a synthetic four-amino-acid peptide built to concentrate inside the inner mitochondrial membrane, where it appears to stabilize cardiolipin, a lipid essential to efficient energy production. Animal work and early human trials have shown promise in conditions tied to mitochondrial dysfunction, including heart failure and kidney injury. It remains investigational rather than broadly approved, and most of what circulates about it online has outrun the actual clinical record.
Is SS-31 peptide legal to buy in the United States after the 2026 crackdown?
It depends entirely on the channel. SS-31 has no FDA approval for general use, so selling it as a finished product for people to inject is not lawful. Since 2026 enforcement tightened the rules around research-chemical vendors, the cleanest compliant route is a physician-supervised prescription filled through a licensed compounding pharmacy, such as FormBlends, working within applicable pharmacy law. Buying raw powder from an unregulated site, domestic or overseas, sits in genuinely risky legal and safety territory.
What side effects have been reported with SS-31 peptide?
In the completed trials, mostly in cardiac and kidney patient populations, tolerability has generally been mild, with injection-site reactions the most common complaint, and occasional nausea or flushing. The human trial base is still small and skews toward sick populations rather than healthy users chasing energy or longevity, so long-term or off-label side effect data is genuinely thin. Anyone self-administering outside medical oversight has no real safety net if something unexpected turns up.
What dosage of SS-31 is used in clinical research?
There’s no established approved dosage, since SS-31 hasn’t cleared that bar outside its narrow Barth syndrome indication. Published trials have used various intravenous and subcutaneous doses, often calculated by body weight, differing by indication and study design. The numbers floating around peptide forums are lifted from these trials and applied without the monitoring that made those trials safe to run in the first place. Without a prescribing physician looking at your actual health picture, any dose you find online is a guess dressed up as a fact.
References
- SS-31 binds with high affinity to cardiolipin on the inner mitochondrial membrane, protecting cristae and re-energizing stressed mitochondria. Birk AV, et al. (Szeto HH senior author). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol, 2013. https://pubmed.ncbi.nlm.nih.gov/23813215/
- Review of elamipretide structure and mechanism: a cell-permeable peptide that targets the inner mitochondrial membrane and stabilizes cristae through cardiolipin. Int J Mol Sci, 2025;26(3):944. https://pubmed.ncbi.nlm.nih.gov/39940712/
- Pivotal phase 3 trial (MMPOWER-3): 218 adults with primary mitochondrial myopathy randomized to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks; no significant difference from placebo on the six-minute walk test or total fatigue, missing primary and secondary endpoints. Karaa A, et al. Neurology, 2023. (full text:)
- Earlier phase 1/2 dose-escalation trial (MMPOWER): short-term IV elamipretide improved six-minute walk distance at the highest dose after 5 days; “elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.” Karaa A, et al. Neurology, 2018.
- Elamipretide described as the first cardiolipin-directed mitochondrial therapeutic granted FDA accelerated approval (September 2025) for Barth syndrome, with a confirmatory trial required. Zhao C, Zhuang X, Gao J. Drug Discov Ther, 2026.
- FDA approval record for elamipretide (Forzinity), NDA 215244: accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. U.S. FDA, Drugs@FDA.
- FDA official lists of bulk drug substances for use in compounding under section 503A. U.S. FDA.
